Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer wins court decision on Avelox

Bayer wins court decision on Avelox

29th October 2007

Bayer has announced that the US District Court for the District of Delaware has decided in its favour in its lawsuit against Dr Reddy’s Laboratories regarding the patents covering Avelox (moxifloxacin Hcl).

Avelox Oral is indicated as a treatment for community-acquired pneumonia, acute bacterial sinusitis and acute exacerbations of chronic bronchitis in Europe, with Avelox IV also approved as a treatment for complicated skin and skin structure infections.

The court rejected all challenges from Dr Reddy’s relating to the validity and enforceability of the two Bayer patents related to its fluoroquinolone antibiotic.

Bayer had brought its lawsuit to the court as a response to Dr Reddy’s filing an abbreviated new drug application with the US Food and Drug Administration for a generic version of the drug before the patents from Bayer had expired.

“Another generic company, Teva Pharmaceuticals USA has also challenged the validity of the same Bayer patents at issue in the Dr Reddy’s case in a case pending in the US District Court for the District of Delaware,” Bayer reports.

The company added that this case is due to start in February 2008, with Bayer prepared to “vigorously” defend its patents.

In October 2006, Schering-Plough released data showing the efficacy of Avelox as a treatment for complex intra-abdominal infections.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.